Drug Trial Radar · NCT05638802
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jun 7, 2023
Primary completion
Apr 1, 2025
Study completion Apr 1, 2025
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Conditions
- Systemic Lupus Erythematosus
Interventions
DS-7011aDrug
20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
PlaceboDrug
Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus ErythematosusTime frame: Post first dose up to Week 24
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Pinnacle Research Group LLC
Anniston, Alabama
Arkansas Research Trials
North Little Rock, Arkansas
Office of Tory P. Sullivan, M.D. - North Miami Beach
North Miami Beach, Florida
West Broward Rheumatology Associates
Tamarac, Florida
The University of Kansas Medical Center
Kansas City, Kansas
Oakland Hills Dermatology
Auburn Hills, Michigan
Revival Research Institute, LLC
Troy, Michigan
MediSearch Clinical Trials
Saint Joseph, Missouri
Joint & Muscle Research Institute
Charlotte, North Carolina
Trinity Health Center Medical Arts
Minot, North Dakota
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Metroplex Clinical Research Center, LLC
Dallas, Texas
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
Shanghai, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Hospital of the University of Occupational and Environmental Health
Kitakyushu-shi, Japan
Japan Community Health Care Organization Chukyo Hospital
Nagoya, Japan
Tohoku University Hospital
Sendai, Japan
Jcho Tokyo Yamate Medical Center
Shinjuku-ku, Japan
Yokohama City University Medical Center
Yokohama, Japan
Phi University Clinic of Rheumatology Skopje
Skopje, North Macedonia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.